Search

Your search keyword '"Secq, Véronique"' showing total 147 results
Start Over Author "Secq, Véronique"
147 results on '"Secq, Véronique"'

3. Novel partial loss-of-function variants in the tyrosyl-tRNA synthetase 1 (YARS1) gene involved in multisystem disease

Author

Estève, Clothilde, Roman, Céline, DeLeusse, Cécile, Baravalle, Melissa, Bertaux, Karine, Blanc, Frédéric, Bourgeois, Patrice, Bresson, Violaine, Cano, Aline, Coste, Marie-Edith, Delteil, Clémence, Lacoste, Caroline, Loosveld, Marie, De Paula, André Maues, Monnier, Anne-Sophie, Secq, Véronique, Levy, Nicolas, Badens, Catherine, and Fabre, Alexandre

Published
2021
Full Text
View/download PDF

5. Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study

Author

Molina, Thierry J., Bluthgen, Maria V., Chalabreysse, Lara, de Montpréville, Vincent T., de Muret, Anne, Dubois, Romain, Hofman, Véronique, Lantuejoul, Sylvie, le Naoures, Cécile, Mansuet-Lupo, Audrey, Parrens, Marie, Piton, Nicolas, Rouquette, Isabelle, Secq, Véronique, Girard, Nicolas, Marx, Alexander, and Besse, Benjamin

Published
2021
Full Text
View/download PDF

6. Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort

Author

Kambouchner, Marianne, Emile, Jean-François, Copin, Marie-Christine, Coulomb-Lherminé, Aurore, Sabourin, Jean-Christophe, Della Valle, Valeria, Sileo, Chiara, Ducou Le Pointe, Hubert, Bégueret, Hugues, Galmiche, Louise, Lambilliotte, Anne, Paraf, François, Piche, Marjorie, Piguet, Christophe, Rullier, Anne, Secq, Véronique, Serre, Isabelle, Bernaudin, Jean-François, and Donadieu, Jean

Published
2019
Full Text
View/download PDF

8. Complex Compound Inheritance of Lethal Lung Developmental Disorders Due to Disruption of the TBX-FGF Pathway

Author

Karolak, Justyna A., Vincent, Marie, Deutsch, Gail, Gambin, Tomasz, Cogné, Benjamin, Pichon, Olivier, Vetrini, Francesco, Mefford, Heather C., Dines, Jennifer N., Golden-Grant, Katie, Dipple, Katrina, Freed, Amanda S., Leppig, Kathleen A., Dishop, Megan, Mowat, David, Bennetts, Bruce, Gifford, Andrew J., Weber, Martin A., Lee, Anna F., Boerkoel, Cornelius F., Bartell, Tina M., Ward-Melver, Catherine, Besnard, Thomas, Petit, Florence, Bache, Iben, Tümer, Zeynep, Denis-Musquer, Marie, Joubert, Madeleine, Martinovic, Jelena, Bénéteau, Claire, Molin, Arnaud, Carles, Dominique, André, Gwenaelle, Bieth, Eric, Chassaing, Nicolas, Devisme, Louise, Chalabreysse, Lara, Pasquier, Laurent, Secq, Véronique, Don, Massimiliano, Orsaria, Maria, Missirian, Chantal, Mortreux, Jérémie, Sanlaville, Damien, Pons, Linda, Küry, Sébastien, Bézieau, Stéphane, Liet, Jean-Michel, Joram, Nicolas, Bihouée, Tiphaine, Scott, Daryl A., Brown, Chester W., Scaglia, Fernando, Tsai, Anne Chun-Hui, Grange, Dorothy K., Phillips, John A., 3rd, Pfotenhauer, Jean P., Jhangiani, Shalini N., Gonzaga-Jauregui, Claudia G., Chung, Wendy K., Schauer, Galen M., Lipson, Mark H., Mercer, Catherine L., van Haeringen, Arie, Liu, Qian, Popek, Edwina, Coban Akdemir, Zeynep H., Lupski, James R., Szafranski, Przemyslaw, Isidor, Bertrand, Le Caignec, Cedric, and Stankiewicz, Paweł

Published
2019
Full Text
View/download PDF

9. AB004. Basaloid carcinoma of the thymus: experience of the RYTHMIC network over an 8-year period

Author

Piton, Nicolas, primary, Mansuet-Lupo, Audrey, additional, Chalabreysse, Lara, additional, Dubois, Romain, additional, Hofman, Véronique, additional, Le Naoures, Cécile, additional, de Montpréville, Vincent Thomas, additional, De Muret, Anne, additional, Parrens, Marie, additional, Rouquette, Isabelle, additional, Secq, Véronique, additional, Dales, Jean-Philippe, additional, Sizaret, Damien, additional, Missy, Pascale, additional, Tran, Quân, additional, Bazéli, Édith, additional, Marx, Alexander, additional, Girard, Nicolas, additional, Besse, Benjamin, additional, and Molina, Thierry Jo, additional

Published
2023
Full Text
View/download PDF

11. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

Author

Nicolle, Rémy, Blum, Yuna, Marisa, Laetitia, Loncle, Celine, Gayet, Odile, Moutardier, Vincent, Turrini, Olivier, Giovannini, Marc, Bian, Benjamin, Bigonnet, Martin, Rubis, Marion, Elarouci, Nabila, Armenoult, Lucile, Ayadi, Mira, Duconseil, Pauline, Gasmi, Mohamed, Ouaissi, Mehdi, Maignan, Aurélie, Lomberk, Gwen, Boher, Jean-Marie, Ewald, Jacques, Bories, Erwan, Garnier, Jonathan, Goncalves, Anthony, Poizat, Flora, Raoul, Jean-Luc, Secq, Veronique, Garcia, Stephane, Grandval, Philippe, Barraud-Blanc, Marine, Norguet, Emmanuelle, Gilabert, Marine, Delpero, Jean-Robert, Roques, Julie, Calvo, Ezequiel, Guillaumond, Fabienne, Vasseur, Sophie, Urrutia, Raul, de Reyniès, Aurélien, Dusetti, Nelson, and Iovanna, Juan

Published
2017
Full Text
View/download PDF

12. Figure S5 from LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker

Author

Bressy, Christian, primary, Lac, Sophie, primary, Nigri, Jérémy, primary, Leca, Julie, primary, Roques, Julie, primary, Lavaut, Marie-Nöelle, primary, Secq, Véronique, primary, Guillaumond, Fabienne, primary, Bui, Thi-Thien, primary, Pietrasz, Daniel, primary, Granjeaud, Samuel, primary, Bachet, Jean-Baptiste, primary, Ouaissi, Mehdi, primary, Iovanna, Juan, primary, Vasseur, Sophie, primary, and Tomasini, Richard, primary

Published
2023
Full Text
View/download PDF

13. Data from LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker

Author

Bressy, Christian, primary, Lac, Sophie, primary, Nigri, Jérémy, primary, Leca, Julie, primary, Roques, Julie, primary, Lavaut, Marie-Nöelle, primary, Secq, Véronique, primary, Guillaumond, Fabienne, primary, Bui, Thi-Thien, primary, Pietrasz, Daniel, primary, Granjeaud, Samuel, primary, Bachet, Jean-Baptiste, primary, Ouaissi, Mehdi, primary, Iovanna, Juan, primary, Vasseur, Sophie, primary, and Tomasini, Richard, primary

Published
2023
Full Text
View/download PDF

14. Supplementary data from LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker

Author

Bressy, Christian, primary, Lac, Sophie, primary, Nigri, Jérémy, primary, Leca, Julie, primary, Roques, Julie, primary, Lavaut, Marie-Nöelle, primary, Secq, Véronique, primary, Guillaumond, Fabienne, primary, Bui, Thi-Thien, primary, Pietrasz, Daniel, primary, Granjeaud, Samuel, primary, Bachet, Jean-Baptiste, primary, Ouaissi, Mehdi, primary, Iovanna, Juan, primary, Vasseur, Sophie, primary, and Tomasini, Richard, primary

Published
2023
Full Text
View/download PDF

15. Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma

Author

Duconseil, Pauline, Gilabert, Marine, Gayet, Odile, Loncle, Celine, Moutardier, Vincent, Turrini, Olivier, Calvo, Ezequiel, Ewald, Jacques, Giovannini, Marc, Gasmi, Mohamed, Bories, Erwan, Barthet, Marc, Ouaissi, Mehdi, Goncalves, Anthony, Poizat, Flora, Raoul, Jean Luc, Secq, Veronique, Garcia, Stephane, Viens, Patrice, Iovanna, Juan, and Dusetti, Nelson

Published
2015
Full Text
View/download PDF

20. Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation

Author

Forel, Jean-Marie, Guervilly, Christophe, Hraiech, Sami, Voillet, François, Thomas, Guillemette, Somma, Claude, and Secq, Véronique

Subjects
Care and treatment, Research, Mortality -- France -- United Kingdom -- Canada -- Research, Medical research, Medicine, Experimental
Abstract

Author(s): Jean-Marie Forel [sup.1] [sup.2], Christophe Guervilly [sup.2], Sami Hraiech [sup.1] [sup.2], François Voillet [sup.2], Guillemette Thomas [sup.1] [sup.2], Claude Somma [sup.3], Véronique Secq [sup.1] [sup.4], Catherine Farnarier [sup.5], Marie-Josée [...], Purpose A specific biomarker of post-ARDS fibroproliferation could be useful in the identification of patients who could benefit from therapies aiming to modulate fibroproliferation such as corticosteroids.The aim of this prospective study was to determine the best threshold of the N-terminal-peptidetype III procollagen (NT-PCP-III) in non-resolving ARDS to validate this threshold according to the outcome. Methods Concerning the best threshold of NT-PCP-III, all consecutive patients with a non-resolving ARDS were included if all the following criteria were fulfilled: moderate to severe ARDS lasting for at least 5 days, lung biopsy performed, serum and alveolar NT-PCP-III obtained within 1 week prior to biopsy, and no documented infection contra-indicating the corticosteroids. In the validation cohort part of the study, patients were included at day 7 if they presented a persistent moderate to severe ARDS. Results Nineteen of 32 patients had fibroproliferatio nonbiopsy. Serum and alveolar NT-PCP-III were higher in patients with fibroproliferation. Using a threshold of 9 [micro]g/L, alveolar NT-PCP-III had the highest accuracy for diagnosing fibroproliferation (sensitivity = 89.5 % and specificity = 92.3 %). Regarding the 51 patients included in the validation cohort, the mortality rate at day 60 was increased in patients presenting an alveolar NT-PCP-III level higher than 9 [micro]g/L (69 vs. 17 %, p < 0.001). The mean alveolar level of NT-PCP-III on day 7 was 8.1-fold higher in nonsurvivors (p = 0.03). Conclusions The determination of NT-PCP-III on BAL done at day 7 in persistent ARDS is able to identify patients with fibroproliferation who could be included in a trial of corticosteroids or any other treatment that might help resolve lung fibroproliferation.

Published
2015
Full Text
View/download PDF

23. Homotypic cell cannibalism, a cell‐death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer

Author

Cano, Carla E, primary, José Sandí, María, additional, Hamidi, Tewfik, additional, Calvo, Ezequiel L, additional, Turrini, Olivier, additional, Bartholin, Laurent, additional, Loncle, Céline, additional, Secq, Véronique, additional, Garcia, Stéphane, additional, Lomberk, Gwen, additional, Kroemer, Guido, additional, Urrutia, Raul, additional, and Iovanna, Juan L, additional

Published
2021
Full Text
View/download PDF

27. Complex Compound Inheritance of Lethal Lung Developmental Disorders due to Disruption of the TBX-FGF Pathway

Author

Karolak, Justyna A, Vincent, Marie, Deutsch, Gail, Gambin, Tomasz, Cogné, Benjamin, Pichon, Olivier, Vetrini, Francesco, Mefford, Heather C, Dines, Jennifer N, Golden-Grant, Katie, Dipple, Katrina, Freed, Amanda S, Leppig, Kathleen A, Dishop, Megan, Mowat, David, Bennetts, Bruce, Gifford, Andrew J, Weber, Martin A, Lee, Anna F, Boerkoel, Cornelius F, Bartell, Tina M, Ward-Melver, Catherine, Besnard, Thomas, Petit, Florence, Bache, Iben, Tümer, Zeynep, Denis-Musquer, Marie, Joubert, Madeleine, Martinovic, Jelena, Bénéteau, Claire, Molin, Arnaud, Carles, Dominique, André, Gwenaelle, Bieth, Eric, Chassaing, Nicolas, Devisme, Louise, Chalabreysse, Lara, Pasquier, Laurent, Secq, Véronique, Don, Massimiliano, Orsaria, Maria, Missirian, Chantal, Mortreux, Jérémie, Sanlaville, Damien, Pons, Linda, Küry, Sébastien, Bézieau, Stéphane, Liet, Jean-Michel, Joram, Nicolas, Bihouée, Tiphaine, Scott, Daryl A, Brown, Chester W, Scaglia, Fernando, Tsai, Anne Chun-Hui, Grange, Dorothy K, Phillips, John A, Pfotenhauer, Jean P, Jhangiani, Shalini N, Gonzaga-Jauregui, Claudia G, Chung, Wendy K, Schauer, Galen M, Lipson, Mark H, Mercer, Catherine L, van Haeringen, Arie, Liu, Qian, Popek, Edwina, Coban Akdemir, Zeynep H, Lupski, James R, Szafranski, Przemyslaw, Isidor, Bertrand, Le Caignec, Cedric, Stankiewicz, Paweł, Karolak, Justyna A, Vincent, Marie, Deutsch, Gail, Gambin, Tomasz, Cogné, Benjamin, Pichon, Olivier, Vetrini, Francesco, Mefford, Heather C, Dines, Jennifer N, Golden-Grant, Katie, Dipple, Katrina, Freed, Amanda S, Leppig, Kathleen A, Dishop, Megan, Mowat, David, Bennetts, Bruce, Gifford, Andrew J, Weber, Martin A, Lee, Anna F, Boerkoel, Cornelius F, Bartell, Tina M, Ward-Melver, Catherine, Besnard, Thomas, Petit, Florence, Bache, Iben, Tümer, Zeynep, Denis-Musquer, Marie, Joubert, Madeleine, Martinovic, Jelena, Bénéteau, Claire, Molin, Arnaud, Carles, Dominique, André, Gwenaelle, Bieth, Eric, Chassaing, Nicolas, Devisme, Louise, Chalabreysse, Lara, Pasquier, Laurent, Secq, Véronique, Don, Massimiliano, Orsaria, Maria, Missirian, Chantal, Mortreux, Jérémie, Sanlaville, Damien, Pons, Linda, Küry, Sébastien, Bézieau, Stéphane, Liet, Jean-Michel, Joram, Nicolas, Bihouée, Tiphaine, Scott, Daryl A, Brown, Chester W, Scaglia, Fernando, Tsai, Anne Chun-Hui, Grange, Dorothy K, Phillips, John A, Pfotenhauer, Jean P, Jhangiani, Shalini N, Gonzaga-Jauregui, Claudia G, Chung, Wendy K, Schauer, Galen M, Lipson, Mark H, Mercer, Catherine L, van Haeringen, Arie, Liu, Qian, Popek, Edwina, Coban Akdemir, Zeynep H, Lupski, James R, Szafranski, Przemyslaw, Isidor, Bertrand, Le Caignec, Cedric, and Stankiewicz, Paweł

Abstract

Primary defects in lung branching morphogenesis, resulting in neonatal lethal pulmonary hypoplasias, are incompletely understood. To elucidate the pathogenetics of human lung development, we studied a unique collection of samples obtained from deceased individuals with clinically and histopathologically diagnosed interstitial neonatal lung disorders: acinar dysplasia (n = 14), congenital alveolar dysplasia (n = 2), and other lethal lung hypoplasias (n = 10). We identified rare heterozygous copy-number variant deletions or single-nucleotide variants (SNVs) involving TBX4 (n = 8 and n = 2, respectively) or FGF10 (n = 2 and n = 2, respectively) in 16/26 (61%) individuals. In addition to TBX4, the overlapping ∼2 Mb recurrent and nonrecurrent deletions at 17q23.1q23.2 identified in seven individuals with lung hypoplasia also remove a lung-specific enhancer region. Individuals with coding variants involving either TBX4 or FGF10 also harbored at least one non-coding SNV in the predicted lung-specific enhancer region, which was absent in 13 control individuals with the overlapping deletions but without any structural lung anomalies. The occurrence of rare coding variants involving TBX4 or FGF10 with the putative hypomorphic non-coding SNVs implies a complex compound inheritance of these pulmonary hypoplasias. Moreover, they support the importance of TBX4-FGF10-FGFR2 epithelial-mesenchymal signaling in human lung organogenesis and help to explain the histopathological continuum observed in these rare lethal developmental disorders of the lung.

Published
2019

28. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid

Author

Frankel, Diane, primary, Nanni-Metellus, Isabelle, additional, Robaglia-Schlupp, Andrée, additional, Tomasini, Pascale, additional, Guinde, Julien, additional, Barlesi, Fabrice, additional, Astoul, Philippe, additional, Ouafik, L’Houcine, additional, Amatore, Florent, additional, Secq, Véronique, additional, Kaspi, Elise, additional, and Roll, Patrice, additional

Published
2018
Full Text
View/download PDF

29. Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts

Author

Bian, Benjamin, Bigonnet, Martin, Gayet, Odile, Loncle, Céline, Maignan, Aurélie, Gilabert, Marine, Moutardier, Vincent, Garcia, Stéphane, Turrini, Olivier, Delpero, Jean-Robert, Giovannini, Marc, Grandval, Philippe, Gasmi, Mohamed, Ouaissi, Mehdi, Secq, Véronique, Poizat, Flora, Nicolle, Rémy, Blum, Yuna, Marisa, Laetitia, Rubis, Marion, Raoul, Jean-Luc, Bradner, James, Qi, Jun, Lomberk, Gwen, Urrutia, Raul, Saúl, Andres, Dusetti, Nelson, Iovanna, Juan, Bidaut, Ghislain, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université - Faculté de médecine (AMU MED), Aix Marseille Université (AMU), Hôpital Nord [CHU - APHM], Department of Surgical Oncology, Université de la Méditerranée - Aix-Marseille 2, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Génétique Médicale et Génomique Fonctionnelle (GMGF), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut Curie [Paris], (le programme) Cartes d'identité des tumeurs (CIT), Ligue Nationales Contre le Cancer (LNCC), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dana-Farber Cancer Institute [Boston], Laboratory of Epigenetics and Chromatin Dynamics, Mayo Clinic, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Institut Curie, Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage [Rennes] (PEGASE), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), and Centre de Recherche Saint-Antoine (CR Saint-Antoine)

Subjects
Adult, Male, Cell Survival, JQ1, [SDV]Life Sciences [q-bio], Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Chromatin, Epigenetics, Genomics & Functional Genomics, Mice, [SDV.CAN] Life Sciences [q-bio]/Cancer, transcriptomic signature, pancreatic adenocarcinoma, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Animals, Humans, bromodomains, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Precision Medicine, Cells, Cultured, Research Articles, Aged, Cancer, Aged, 80 and over, Gene Expression Profiling, Azepines, Middle Aged, Triazoles, Chromatin, Pancreatic Neoplasms, [SDV] Life Sciences [q-bio], c-MYC, c‐MYC, Genomics and Functional Genomics, Heterografts, Female, Epigenetics, Research Article
Abstract

International audience; c-MYC controls more than 15% of genes responsible for proliferation , differentiation, and cellular metabolism in pancreatic as well as other cancers making this transcription factor a prime target for treating patients. The transcriptome of 55 patient-derived xenografts show that 30% of them share an exacerbated expression profile of MYC transcriptional targets (MYC-high). This cohort is characterized by a high level of Ki67 staining, a lower differentiation state, and a shorter survival time compared to the MYC-low subgroup. To define classifier expression signature, we selected a group of 10 MYC target transcripts which expression is increased in the MYC-high group and six transcripts increased in the MYC-low group. We validated the ability of these markers panel to identify MYC-high patient-derived xenografts from both: discovery and validation cohorts as well as primary cell cultures from the same patients. We then showed that cells from MYC-high patients are more sensitive to JQ1 treatment compared to MYC-low cells, in monolayer, 3D cultured spheroids and in vivo xenografted tumors, due to cell cycle arrest followed by apoptosis. Therefore, these results provide new markers and potentially novel therapeutic modalities for distinct subgroups of pancreatic tumors and may find application to the future management of these patients within the setting of individualized medicine clinics.

Published
2017
Full Text
View/download PDF

30. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker

Author

Bressy, Christian, primary, Lac, Sophie, additional, Nigri, Jérémy, additional, Leca, Julie, additional, Roques, Julie, additional, Lavaut, Marie-Nöelle, additional, Secq, Véronique, additional, Guillaumond, Fabienne, additional, Bui, Thi-Thien, additional, Pietrasz, Daniel, additional, Granjeaud, Samuel, additional, Bachet, Jean-Baptiste, additional, Ouaissi, Mehdi, additional, Iovanna, Juan, additional, Vasseur, Sophie, additional, and Tomasini, Richard, additional

Published
2018
Full Text
View/download PDF

31. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Author

Benyamine, Audrey, primary, Loncle, Céline, additional, Foucher, Etienne, additional, Blazquez, Juan-Luis, additional, Castanier, Céline, additional, Chrétien, Anne-Sophie, additional, Modesti, Mauro, additional, Secq, Véronique, additional, Chouaib, Salem, additional, Gironella, Meritxell, additional, Vila-Navarro, Elena, additional, Montalto, Giuseppe, additional, Dagorn, Jean-Charles, additional, Dusetti, Nelson, additional, Iovanna, Juan, additional, and Olive, Daniel, additional

Published
2017
Full Text
View/download PDF

32. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness

Author

Leca, Julie, primary, Martinez, Sébastien, additional, Lac, Sophie, additional, Nigri, Jérémy, additional, Secq, Véronique, additional, Rubis, Marion, additional, Bressy, Christian, additional, Sergé, Arnauld, additional, Lavaut, Marie-Noelle, additional, Dusetti, Nelson, additional, Loncle, Céline, additional, Roques, Julie, additional, Pietrasz, Daniel, additional, Bousquet, Corinne, additional, Garcia, Stéphane, additional, Granjeaud, Samuel, additional, Ouaissi, Mehdi, additional, Bachet, Jean Baptiste, additional, Brun, Christine, additional, Iovanna, Juan L., additional, Zimmermann, Pascale, additional, Vasseur, Sophie, additional, and Tomasini, Richard, additional

Published
2016
Full Text
View/download PDF

33. Severe Pulmonary Fibrosis as the First Manifestation of Interferonopathy (TMEM173 Mutation)

Author

Picard, Cécile, primary, Thouvenin, Guillaume, additional, Kannengiesser, Caroline, additional, Dubus, Jean-Christophe, additional, Jeremiah, Nadia, additional, Rieux-Laucat, Frédéric, additional, Crestani, Bruno, additional, Belot, Alexandre, additional, Thivolet-Béjui, Françoise, additional, Secq, Véronique, additional, Ménard, Christelle, additional, Reynaud-Gaubert, Martine, additional, and Reix, Philippe, additional

Published
2016
Full Text
View/download PDF

37. PAP/HIP protein is an obesogenic factor

Author

Secq, Véronique, Mallmann, Cecilia, Gironella, Meritxell, López, Belén, Closa, Daniel, García, Stéphane, Christa, Laurence, Montalto, Giuseppe, Dusetti, Nelson, Iovanna, Juan Lucio, Secq, V, Mallmann, C, Gironella, M, Lopez, B, Closa, D, Garcia, S, Christa, L, Montalto, G, Dusetti, N, and Iovanna, JL

Subjects
Transgenic mice, PAP/HIP, Severe obesity
Abstract

In this article we report the obesogenic role of the acute phase protein PAP/HIP. We found that the transgenic TgPAP/HIP mice develop spontaneous obesity under standard nutritional conditions, with high levels of glucose, leptin, and LDL and low levels of triglycerides and HDL in blood. Accordingly, PAP/HIP-deficient mice are skinny under standard nutritional conditions. We also found that expression of PAP/HIP is induced in intestinal epithelial cells in response to gavage with olive oil and this induction is AG490 sensitive. We demonstrated that incubation of 3T3-L1 preadipocytes with a low concentration as 1ng/ml of recombinant PAP/HIP results in accelerated BrdU incorporation in vitro. PAP/HIP-dependent adipocytes growth is sensitive to the MEK inhibitor U0126. Finally, patients with severe obesity present higher blood levels of PAP/HIP than non-obese control individuals. Altogether our data suggest that PAP/HIP could be a mediator of fat tissue development, released by the intestine and induced by the presence of food into the gut. © 2013 Wiley Periodicals, Inc., Funded by: INSERM.

Published
2014

38. Regional molecular genetics centers in thoracic oncology: what and who should be tested?

Author

Barlési, Fabrice, Tomasini, Pascale, Fina, Frédéric, Secq, Véronique, Greillier, Laurent, Nanni-Metellus, Isabelle, Garcia, Stéphane, Ouafik, L'Houcine, Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Institut National de la Santé et de la Recherche Médicale (INSERM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Aix Marseille Université (AMU), Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], service hospitalier d'anatomie et cytologie pathologique humaine, APHM, Marseille, Assistance Publique - Hôpitaux de Marseille (APHM), Ouafik, L'Houcine, Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)

Subjects
personalized therapy, lung cancer, french NCI, [SDV.CAN] Life Sciences [q-bio]/Cancer, molecular profiling, bioguided treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, molecular genetics center
Abstract

International audience; Management of NSCLC patients is more and more individualized especially on the base of bioguided treatments. In order to guarantee an access for all the patients too this type of strategy, the French NCI supports since 2006 a nationwide network of 28 regional genetics center. The financial support is based on public funds. The French NCI recommends today the assessment of seven biomarkers for all stage IV non squamous NSCLC patients. Due to financial and technical reasons, this recommendation must be followed. However, the molecular profiling of lung cancer patients would ideally be extended across all stages and all histological types of the disease in order to improve our knowledge in this field and provides the patient with an opportunity to access a bioguided treatment as frequently as possible.

Published
2013

39. Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches

Author

Even-Desrumeaux, Klervi, Fourquet, Patrick, Secq, Véronique, Baty, Daniel, Chames, Patrick, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie de Marseille - Luminy (CIML), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), and This work was supported by the ANR (Agence Nationale de Recherche) program 'Nanosciences and Nanotechnologies' under the grant ANR-07-PNANO-051-01 and by the ARC (Association pour la Recherche contre le Cancer).

Subjects
[SDV.BIO]Life Sciences [q-bio]/Biotechnology, Single domain antibodies, cancer, diagnostic, biomarkers, beads array, [INFO.INFO-BT]Computer Science [cs]/Biotechnology
Abstract

International audience; Noninvasive early detection of breast cancer through the use of biomarkers is urgently needed since the risk of recurrence, morbidity, and mortality is closely related to disease stage at the time of primary surgery. A crucial issue in this approach is the availability of relevant markers and corresponding monoclonal antibodies suitable for the development of effective immunodiagnostic modalities. The identification of such markers from human pathological lesions and the isolation of specific antibodies using conventional approaches remain major challenges. Camelids produce functional antibodies devoid of light chains in which the single N-terminal domain of the heavy chain is fully capable of antigen binding. When produced as an independent domain, these so-called single-domain antibody fragments (sdAbs) or nanobodies have several advantages for biotechnological applications owing to their unique properties of size (13 kDa), stability, solubility, and expression yield. In this work, we have generated phage display libraries from animals immunized with breast cancer biopsies. These libraries were used to isolate sdAbs against known and relevant antigens such as HER2, or several cancer-specific sdAbs against unknown targets. We describe the identification of one these targets, cytokeratin 19, using affinity purification in combination with mass spectrometry. Some of these sdAbs were used in several straightforward diagnostic applications such as immunohistochemical analysis of tumor samples, multiplexed cytometric bead array analysis of crude samples, or an immune enrichment procedure of rare cells. Here, we demonstrate that phage display-based selection of single-domain antibodies is an efficient and high-throughput compatible approach to generate binders with excellent characteristics for the fast development of diagnostic and prognostic modalities.

Published
2012
Full Text
View/download PDF

40. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes

Author

Thomas de Montpréville, Vincent, primary, Quilhot, Pauline, additional, Chalabreysse, Lara, additional, De Muret, Anne, additional, Hofman, Véronique, additional, Lantuéjoul, Sylvie, additional, Parrens, Marie, additional, Payan, Marie-José, additional, Rouquette, Isabelle, additional, Secq, Véronique, additional, Girard, Nicolas, additional, Besse, Benjamin, additional, Marx, Alexander, additional, and Molina, Thierry Jo, additional

Published
2015
Full Text
View/download PDF

41. Abstract B06: Impact of intratumoral microenvironment and epithelial cells crosstalk in pancreatic carcinogenesis

Author

Leca, Julie, primary, Secq, Véronique, additional, Nigri, Jérémy, additional, Martinez, Sébastien, additional, Rubis, Marion, additional, Lavaut, Marie Noelle, additional, Dusetti, Nelson, additional, Loncle, Céline, additional, Garcia, Stéphane, additional, Chan, Philippe, additional, Benard, Magalie, additional, Iovanna, Juan Lucio, additional, Brun, Christine, additional, Vasseur, Sophie, additional, and Tomasini, Richard, additional

Published
2015
Full Text
View/download PDF

42. Novel therapeutic targets for pancreatic adenocarcinoma revealed by a multi-omics analysis of patient-derived xenografts

Author

Nicolle, Rémy, Blum, Yuna, Marisa, Laetitia, Loncle, Celine, Gayet, Odile, Moutardier, Vincent, Turrini, Olivier, Giovannini, Marc, Bian, Benjamin, Bigonnet, Martin, Rubis, Marion, Duconseil, Pauline, Gasmi, Mohamed, Lomberk, Gwen, Ewald, Jacques, Bories, Erwan, Poizat, Flora, Raoul, Jean-luc, Secq, Veronique, Garcia, Stephane, Grandval, Philippe, Gilabert, Marine, Delpero, Jean-Robert, Roques, Julie, Guillaumond, Fabienne, Vasseur, Sophie, Urrutia, Raul, de Reyniès, Aurélien, Dusetti, Nelson, and Iovanna, Juan

Published
2017
Full Text
View/download PDF

43. Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation

Author

Forel, Jean-Marie, primary, Guervilly, Christophe, additional, Hraiech, Sami, additional, Voillet, François, additional, Thomas, Guillemette, additional, Somma, Claude, additional, Secq, Véronique, additional, Farnarier, Catherine, additional, Payan, Marie-Josée, additional, Donati, Stéphanie-Yannis, additional, Perrin, Gilles, additional, Trousse, Delphine, additional, Dizier, Stéphanie, additional, Chiche, Laurent, additional, Baumstarck, Karine, additional, Roch, Antoine, additional, and Papazian, Laurent, additional

Published
2014
Full Text
View/download PDF

44. Prognostic factors of response to adjuvant chemotherapy after curative resection for pancreatic ductal adenocarcinoma: Prognostic impact of CDA, predictive value of DPD for 5FU efficiency, and hENT1 for gemcitabine.

Author

Truchet, Xavier Edouard, primary, Mallaret, Claire, additional, Secq, Véronique, additional, Mancini, Julien, additional, le Treut, Yves patrice, additional, Moutardier, Vincent, additional, Ouaïssi, Mehdi, additional, Rubis, Marion, additional, Nouguered, Emilie, additional, Delgrande, Jean, additional, Lavaut, marie-Noëlle, additional, Ciccolini, Joseph, additional, Gasmi, Mohamed, additional, Garcia, Stéphane, additional, Seitz, Jean Francois, additional, and Dahan, Laetitia, additional

Published
2014
Full Text
View/download PDF

45. PAP/HIP protein is an obesogenic factor

Author

Secq, Véronique, Mallmann, Cecilia, Gironella, Meritxell, López, Belén, Closa, Daniel, García, Stéphane, Christa, Laurence, Montalto, Giuseppe, Dusetti, Nelson, Iovanna, Juan Lucio, Secq, Véronique, Mallmann, Cecilia, Gironella, Meritxell, López, Belén, Closa, Daniel, García, Stéphane, Christa, Laurence, Montalto, Giuseppe, Dusetti, Nelson, and Iovanna, Juan Lucio

Abstract

In this article we report the obesogenic role of the acute phase protein PAP/HIP. We found that the transgenic TgPAP/HIP mice develop spontaneous obesity under standard nutritional conditions, with high levels of glucose, leptin, and LDL and low levels of triglycerides and HDL in blood. Accordingly, PAP/HIP-deficient mice are skinny under standard nutritional conditions. We also found that expression of PAP/HIP is induced in intestinal epithelial cells in response to gavage with olive oil and this induction is AG490 sensitive. We demonstrated that incubation of 3T3-L1 preadipocytes with a low concentration as 1ng/ml of recombinant PAP/HIP results in accelerated BrdU incorporation in vitro. PAP/HIP-dependent adipocytes growth is sensitive to the MEK inhibitor U0126. Finally, patients with severe obesity present higher blood levels of PAP/HIP than non-obese control individuals. Altogether our data suggest that PAP/HIP could be a mediator of fat tissue development, released by the intestine and induced by the presence of food into the gut. © 2013 Wiley Periodicals, Inc.

Published
2013

46. Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs

Author

Gilabert, Marine, primary, Vaccaro, Maria Inés, additional, Fernandez‐Zapico, Martin E., additional, Calvo, Ezequiel L., additional, Turrini, Olivier, additional, Secq, Véronique, additional, Garcia, Stéphane, additional, Moutardier, Vincent, additional, Lomberk, Gwen, additional, Dusetti, Nelson, additional, Urrutia, Raul, additional, and Iovanna, Juan L., additional

Published
2013
Full Text
View/download PDF

49. Transcriptome analysis predicts clinical outcome and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma

Author

Duconseil, Pauline, Gilabert, Marine, Gayet, Odile, Loncle, Céline, Moutardier, Vincent, Turrini, Olivier, Calvo, Ezequiel, Ewald, Jacques, Giovannini, Marc, Gasmi, Mohamed, Bories, Erwan, Barthet, Marc, Ouaissi, Mehdi, Goncalves, Anthony, Jean-Luc, Raoul, Secq, Veronique, Garcia, Stephane, Viens, Patrice, Iovanna, Juan, and Dusetti, Nelson

Published
2014
Full Text
View/download PDF

50. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

Author

Benyamine, Audrey, Loncle, Céline, Foucher, Etienne, Blazquez, Juan-Luis, Castanier, Céline, Chrétien, Anne-Sophie, Modesti, Mauro, Secq, Véronique, Chouaib, Salem, Gironella, Meritxell, Vila-Navarro, Elena, Montalto, Giuseppe, Dagorn, Jean-Charles, Dusetti, Nelson, Iovanna, Juan, and Olive, Daniel

Subjects
ADENOCARCINOMA, CANCER treatment, IMMUNOTHERAPY, T cells, THERAPEUTICS
Abstract

Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the agonist anti-BTN3A 20.1 mAb even under conditions of hypoxia. In PDAC primary tumors, we established that BTN3A expression and high plasma levels of soluble BTN3A were strongly associated with a decreased survival. These findings may have important implications in the design of new immunotherapeutic strategies that target BTN3A for treating PDAC. [ABSTRACT FROM PUBLISHER]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results